KMT2A and mixed phenotype acute leukemia: Of note, consistent with being a pediatric MPAL cohort, the TARGET cohort included genetic subgroups characteristic of MPAL (17.4% ZNF384-rearranged, 10.1% KMT2A-rearranged, 2.9% BCL11B-rearranged) and diverse pathogenic mutation profiles, suggesting that a differentiation-potential prognostic metric may be applicable across genetic subtypes (Supplementary Data 9).